1. Home
  2. KNSA vs RQI Comparison

KNSA vs RQI Comparison

Compare KNSA & RQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • RQI
  • Stock Information
  • Founded
  • KNSA 2015
  • RQI 2002
  • Country
  • KNSA United Kingdom
  • RQI United States
  • Employees
  • KNSA N/A
  • RQI N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • RQI Trusts Except Educational Religious and Charitable
  • Sector
  • KNSA Health Care
  • RQI Finance
  • Exchange
  • KNSA Nasdaq
  • RQI Nasdaq
  • Market Cap
  • KNSA 2.0B
  • RQI 1.7B
  • IPO Year
  • KNSA 2018
  • RQI N/A
  • Fundamental
  • Price
  • KNSA $26.03
  • RQI $12.37
  • Analyst Decision
  • KNSA Strong Buy
  • RQI
  • Analyst Count
  • KNSA 6
  • RQI 0
  • Target Price
  • KNSA $38.00
  • RQI N/A
  • AVG Volume (30 Days)
  • KNSA 677.6K
  • RQI 432.6K
  • Earning Date
  • KNSA 04-29-2025
  • RQI 01-01-0001
  • Dividend Yield
  • KNSA N/A
  • RQI 8.20%
  • EPS Growth
  • KNSA N/A
  • RQI N/A
  • EPS
  • KNSA N/A
  • RQI N/A
  • Revenue
  • KNSA $481,166,000.00
  • RQI N/A
  • Revenue This Year
  • KNSA $37.21
  • RQI N/A
  • Revenue Next Year
  • KNSA $1.53
  • RQI N/A
  • P/E Ratio
  • KNSA N/A
  • RQI N/A
  • Revenue Growth
  • KNSA 59.45
  • RQI N/A
  • 52 Week Low
  • KNSA $17.38
  • RQI $9.17
  • 52 Week High
  • KNSA $28.56
  • RQI $12.64
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 63.21
  • RQI 57.16
  • Support Level
  • KNSA $25.97
  • RQI $12.21
  • Resistance Level
  • KNSA $28.56
  • RQI $12.55
  • Average True Range (ATR)
  • KNSA 1.24
  • RQI 0.20
  • MACD
  • KNSA 0.36
  • RQI 0.07
  • Stochastic Oscillator
  • KNSA 71.70
  • RQI 82.00

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About RQI Cohen & Steers Quality Income Realty Fund Inc

COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.

Share on Social Networks: